ReviewGene therapy2009
Long-term control of neuropathic pain in a non-viral gene therapy paradigm.
Review in Gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Research progress on composite nerve guidance conduits with immune-regulatory functions.Frontiers in immunology · 2025Review
- Prevention and reversal of neuropathic pain by near-infrared photobiomodulation therapy in male and female rats.Physiology & behavior · 2024Article
- Intrathecal non-viral interleukin-10 gene therapy ameliorates neuropathic pain as measured by both classical static allodynia and a novel supra-spinally mediated pain assay, the Two-Arm Rodent Somatosensory (TARS) task.Brain, behavior, and immunity · 2023Article
- Neuroimmune modulation of pain and regenerative pain medicine.The Journal of clinical investigation · 2020Review
- Effects of spinal non-viral interleukin-10 gene therapy formulated with d-mannose in neuropathic interleukin-10 deficient mice: Behavioral characterization, mRNA and protein analysis in pain relevant tissues.Brain, behavior, and immunity · 2018Article
- Anti-nociceptive and anti-inflammatory actions of sulforaphane in chronic constriction injury-induced neuropathic pain mice.Inflammopharmacology · 2017Article
- AAV-Mediated Gene Transfer to Dorsal Root Ganglion.Methods in molecular biology (Clifton, N.J.) · 2016Article
- The therapeutic potential of interleukin-10 in neuroimmune diseases.Neuropharmacology · 2015Review
- IL-10 and IL-1β mediate neuropathic-pain like behavior in the ventrolateral orbital cortex.Neurochemical research · 2015Article
- Neuroimmune mechanisms of stress: sex differences, developmental plasticity, and implications for pharmacotherapy of stress-related disease.Stress (Amsterdam, Netherlands) · 2015Review
- Emerging targets in neuroinflammation-driven chronic pain.Nature reviews. Drug discovery · 2014Review
- Improvement of spinal non-viral IL-10 gene delivery by D-mannose as a transgene adjuvant to control chronic neuropathic pain.Journal of neuroinflammation · 2014Article
- Glia and pain: is chronic pain a gliopathy?Pain · 2013Review
- Platelet-rich plasma and the elimination of neuropathic pain.Molecular neurobiology · 2013Review
- Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Interleukin-10 of red nucleus plays anti-allodynia effect in neuropathic pain rats with spared nerve injury.Neurochemical research · 2012Article
- Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia.Brain and behavior · 2012Article
- Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration.Pharmaceutical research · 2010Article
- Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy.Journal of biomedicine & biotechnology · 2010Review
- The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia.Trends in pharmacological sciences · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Traditional approaches to treating chronic neuropathic pain largely focus on manipulations directly altering neuronal activity or neuron-to-neuron communication. Recently, however, it has become clear that glial cells (including microglia and astroglia) play a significant role in pain expression in a variety of neuropathic pain models. Multiple aspects of the inflammatory response of glial cells, commonly observed in neuropathic pain conditions, have been implicated in pain expression. Thus, glial cell inflammation has emerged as a potential therapeutic target in neuropathic pain. Our laboratory has been exploring the use of an anti-inflammatory cytokine, interleukin-10 (IL-10), to control glial inflammatory activation thereby controlling neuropathic pain. IL-10 protein delivery is limited by a short half-life and an inability to cross into the central nervous system from the periphery, making a centrally delivered gene therapy approach attractive. We have recently characterized a non-viral gene therapy approach using two injections of naked DNA to achieve long-term (>3 months) control of neuropathic pain in a peripheral nerve injury model. Timing and dose requirements leading to long-term pain control are discussed in this review, as is recent work using microparticle-encapsulated DNA to achieve long-term therapeutic efficacy with a single injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.